Metabolomic Profiles: A Biomarker for the Biological Treatment of RA

“In our study, several amines were found to be significantly associated with DAS28 (six out of seven negatively), CRP (all 12 positively) and ESR (four out of five positively),” write the authors. “Of those amines negatively related with DAS28, histidine, asparagine and threonine were reported to be down regulated in RA patients compared with healthy controls.”

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

Reference

Cuppen BV, Fu J, van Wietmarschen HA, et al. Exploring the inflammatory metabolomic profile to predict response to TNF-α inhibitors in rheumatoid arthritis. PLoS One. 2016 Sep 15;11(9):e0163087. doi: 10.1371/journal.pone.0163087. eCollection 2016.

WASHINGTON, D.C.—Clinical aspects of managing patients with rheumatoid arthritis (RA) in remission were discussed by a panel of experts at the 2016 ACR/ARHP Annual Meeting during the session titled Rheumatoid Arthritis—Clinical Aspects IV: Managing Patients in Remission. Among the issues raised were strategies to taper or discontinue biologic therapies, as well as clinical predictors of…

Narcotic and non-narcotic pain regimens can be used

As the capabilities of machine learning and artificial intelligence improve, rheumatologists have access to more data than ever, which may enable them to better predict which patients will respond to specific treatments, such as tumor necrosis factor inhibitors.

Recent research indicates tumor necrosis factor inhibitors may slow disease progression in the spine of patients with axial spondyloarthritis.

Drug Reduction Strategies, Disease Control for Patients with RA in Remission

How to Manage Pain in Patients with Renal Insufficiency or End-Stage Renal Disease on Dialysis

Beyond Trial & Error: RheumMadness 2022 AI: TNFi Response Scouting Report

Tumor Necrosis Factor Inhibitors May Slow the Progression of Spondyloarthritis

Related Articles